PL2666016T3 - Zastosowanie BUBR1 jako biomarkera odpowiedzi lekowej - Google Patents

Zastosowanie BUBR1 jako biomarkera odpowiedzi lekowej

Info

Publication number
PL2666016T3
PL2666016T3 PL12701341T PL12701341T PL2666016T3 PL 2666016 T3 PL2666016 T3 PL 2666016T3 PL 12701341 T PL12701341 T PL 12701341T PL 12701341 T PL12701341 T PL 12701341T PL 2666016 T3 PL2666016 T3 PL 2666016T3
Authority
PL
Poland
Prior art keywords
bubr1
biomarker
drug response
drug
response
Prior art date
Application number
PL12701341T
Other languages
English (en)
Inventor
Heidi Alexandra Lane
Felix Bachmann
Madlaina Breuleux
Michael Boutros
Daniel Gilbert
Xian Zhang
Original Assignee
Basilea Pharmaceutica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basilea Pharmaceutica Ag filed Critical Basilea Pharmaceutica Ag
Publication of PL2666016T3 publication Critical patent/PL2666016T3/pl

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5026Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell morphology
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/91Transferases (2.)
    • G01N2333/912Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205Phosphotransferases in general
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/44Multiple drug resistance
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
PL12701341T 2011-01-21 2012-01-19 Zastosowanie BUBR1 jako biomarkera odpowiedzi lekowej PL2666016T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11151677 2011-01-21
EP12701341.5A EP2666016B1 (en) 2011-01-21 2012-01-19 Use of bubr1 as a biomarker of drug response to furazanobenzimidazoles

Publications (1)

Publication Number Publication Date
PL2666016T3 true PL2666016T3 (pl) 2017-07-31

Family

ID=43920866

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12701341T PL2666016T3 (pl) 2011-01-21 2012-01-19 Zastosowanie BUBR1 jako biomarkera odpowiedzi lekowej

Country Status (12)

Country Link
US (2) US10222377B2 (pl)
EP (1) EP2666016B1 (pl)
JP (1) JP6302673B2 (pl)
CN (1) CN103314295B (pl)
AU (1) AU2012208520B2 (pl)
CA (2) CA3142576A1 (pl)
DK (1) DK2666016T3 (pl)
ES (1) ES2620582T3 (pl)
HU (1) HUE032643T2 (pl)
PL (1) PL2666016T3 (pl)
PT (1) PT2666016T (pl)
WO (1) WO2012098207A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6334393B2 (ja) * 2011-03-29 2018-05-30 バジリア ファルマスーチカ アーゲーBasilea Pharmaceutica AG 薬物応答のバイオマーカーとしてのホスホAktの使用
WO2015173341A1 (en) * 2014-05-13 2015-11-19 Basilea Pharmaceutica Ag Dosage principle for anti-cancer furazanylbenzimidazoles
EP3365680A1 (en) 2015-10-22 2018-08-29 Basilea Pharmaceutica International AG Use of eb1 as a biomarker of drug response
MX388196B (es) 2017-04-26 2025-03-19 Basilea Pharm Int Ag Procesos para la preparacion de furazanobencimidazoles y formas cristalinas de estos.
US11633383B2 (en) 2017-05-16 2023-04-25 Basilea Pharmaceutica International AG Dosage principle for drugs useful for treating neoplastic diseases
CN107119137B (zh) * 2017-05-26 2018-04-06 广州华弘生物科技有限公司 一种快速检测HER‑2/neu基因表达的检测试剂盒
WO2019097073A1 (en) 2017-11-20 2019-05-23 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
WO2022053549A1 (en) 2020-09-10 2022-03-17 Basilea Pharmaceutica International AG Use of c-myc as a biomarker of drug response

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056910A1 (en) * 1997-06-11 1998-12-17 Chiron Corporation DETECTION OF LOSS OF THE WILD-TYPE huBUB1 GENE
US6593098B1 (en) 1997-12-01 2003-07-15 Fox Chase Cancer Center Genes encoding proteins involved in mitotic checkpoint control and methods of use thereof
ATE553112T1 (de) * 2001-02-21 2012-04-15 Novartis Vaccines & Diagnostic Ttk in der diagnose und als therapeutisches target bei krebs
US7407946B2 (en) * 2002-12-24 2008-08-05 Astrazeneca Ab Quinazoline compounds
EP1636215B1 (en) * 2003-05-23 2008-01-23 Basilea Pharmaceutica AG Furazanobenzimidazoles
US8021831B2 (en) * 2003-08-25 2011-09-20 Board Of Regents, The University Of Texas System Taxane chemosensitivity prediction test
US20050136177A1 (en) 2003-08-25 2005-06-23 Anthony Hesse Method for coloring landscaping materials using foamable dry colorant
CN102605066A (zh) * 2004-12-08 2012-07-25 安万特药物公司 测量对多西他赛抗药性或敏感性的方法
JP2009173629A (ja) * 2007-12-21 2009-08-06 Banyu Pharmaceut Co Ltd Rsk1阻害作用を有する新規スピロインダン誘導体
EP2303891B1 (en) * 2008-06-26 2016-02-17 Les Laboratoires Servier Pyrazolo-quinazolines as protein kinase activity modulators
MX336240B (es) 2009-07-27 2016-01-13 Basilea Pharmaceutica Ag Furazanobencimidazoles como profarmacos para tratar las enfermedades neoplasicas o autoinmunologicas.

Also Published As

Publication number Publication date
CN103314295A (zh) 2013-09-18
EP2666016A1 (en) 2013-11-27
US20160320397A1 (en) 2016-11-03
CN103314295B (zh) 2016-03-16
DK2666016T3 (en) 2017-04-10
CA2822491C (en) 2023-02-14
HK1189056A1 (zh) 2014-05-23
PT2666016T (pt) 2017-04-03
CA3142576A1 (en) 2012-07-26
AU2012208520B2 (en) 2016-03-10
US10222377B2 (en) 2019-03-05
EP2666016B1 (en) 2017-01-04
CA2822491A1 (en) 2012-07-26
ES2620582T3 (es) 2017-06-29
JP6302673B2 (ja) 2018-03-28
US9970938B2 (en) 2018-05-15
NZ611805A (en) 2015-05-29
US20140045897A1 (en) 2014-02-13
JP2014505877A (ja) 2014-03-06
AU2012208520A1 (en) 2013-07-04
WO2012098207A1 (en) 2012-07-26
HUE032643T2 (en) 2017-10-30

Similar Documents

Publication Publication Date Title
SMT201600476B (it) Tenofovir alafenammide emifumarato
SMT201600308B (it) Composti di benzene arile-o eteroarile-sostituiti
DE112012003620T8 (de) Kartusche
CO6890099A2 (es) Nuevos derivados dihidroquinolina-2-ona
EP2743656A4 (en) SPECTROSCOPE
EP2709645A4 (en) ENHANCED PEPTIDE PHARMACEUTICAL AGENTS
BR112014012016A2 (pt) compostos
CO6910197A2 (es) Compuestos novedosos
DE102011100082A8 (de) Traygreifvorrichtung
EP2765427A4 (en) Probe unit
FR2958287B1 (fr) Microreacteur
IL239447A0 (en) Novel compounds
EP2743655A4 (en) SPECTROSCOPE
BR112014000879A2 (pt) deflegmador
CO6960543A2 (es) 2-tiopirimidinonas
PL2666016T3 (pl) Zastosowanie BUBR1 jako biomarkera odpowiedzi lekowej
BR112014009319A2 (pt) compostos farmacêuticos
CO6970601A2 (es) Nueva combinación
BR112014012043A2 (pt) emplastro
EP2654196A4 (en) CONVERTER
DE112011104936A5 (de) Stanzstauchniet
DE112012000958A5 (de) Handsäge
EP2775735A4 (en) ULTRASONIC SENSOR
BR112013022508A2 (pt) novos compostos de azaespirodecanona
FI20115271A7 (fi) Pohjallinen